Show simple item record

dc.contributor.authorTrumper, L.
dc.contributor.authorPro, B.
dc.contributor.authorHorwitz, S.
dc.contributor.authorO'Connor, O.
dc.contributor.authorTilly, H.
dc.contributor.authorChoi, I.
dc.contributor.authorGritti, G.
dc.contributor.authorFox, C.
dc.contributor.authorAlpdogan, O.
dc.contributor.authorMayer, J.
dc.contributor.authorBriones, J.
dc.contributor.authorJacobsen, E.
dc.contributor.authorPezzutto, A.
dc.contributor.authorDemeter, J.
dc.contributor.authorGurion, R.
dc.contributor.authorJurczak, W.
dc.contributor.authorKuo, C. Y.
dc.contributor.authorOpat, S.
dc.contributor.authorLittle, M.
dc.contributor.authorBrown, L.
dc.contributor.authorPuhlmann, M.
dc.contributor.authorIllidge, Timothy M
dc.date.accessioned2020-11-16T07:49:18Z
dc.date.available2020-11-16T07:49:18Z
dc.date.issued2020en
dc.identifier.citationTrumper L, Pro B, Horwitz S, O'Connor O, Tilly H, Choi I, et al. Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2). Oncology Research and Treatment. 2020;43(SUPPL 4):119-en
dc.identifier.urihttp://hdl.handle.net/10541/623444
dc.description.abstractIntroduction: Retreatment of pts with relapsed CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma (sALCL) with BV monotherapy showed encouraging antitumor activity (Bartlett 2014). We report exploratory analyses of pts in the phase 3 ECHELON-2 study (NCT01777152) retreated with BV after frontline BV + cyclophosphamide, doxorubicin, and prednisone (A+CHP). Methods: In ECHELON-2, data on subsequent anticancer therapies were collected, including BV-based regimens, after frontline A+CHP or CHP+vincristine. Investigator response assessments used the Revised Response Criteria for Malignant Lymphoma (Cheson 2007). Safety data were not collected for subsequent anticancer therapy. Results: In total, 10% of A+CHP pts (23/226) were retreated with BV after PD (median age 62 yrs [range 26-77]). Most had ALK- sALCL (16/23 [70%]). Objective response rate (best response) per investigator (INV) after frontline A+CHP was 91% (21/23 [15 CR, 6 PR]); 2 pts (9%) had a best response of SD. Thirteen pts (57%) received consolidative stem cell transplant (SCT) after frontline therapy, 6 pts (26%) received intervening therapy before BV retreatment. In most pts (19/23 [83%]), first retreatment was BV monotherapy. Median time from frontline therapy to retreatment was 12.3 mos (range 3-50). ORR per INV after initial BV retreatment was 57% (13/23 [10 CR, 3 PR]) (Table). Median duration of initial BV retreatment was 2.1 mos (range 0-18). Four pts who had a CR with frontline A+CHP received >1 subsequent retreatment with BV. Of these, 2 pts had a CR after initial BV retreatment, 1 pt had PD after initial BV retreatment and a CR after allo- SCT and subsequent BV retreatment, and 1 pt had a CR after 3 subsequent BV retreatments. Conclusions: In this post-hoc analysis of ECHELON-2 pts who were retreated with BV after frontline A+CHP, 57% had an objective response to BV retreatment in first relapse. Therefore BV retreatment is active in relapsed treatment even after relapsed treatment.en
dc.language.isoenen
dc.titleExploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniv Med Gottingen, Gottingen, Germanyen
dc.identifier.journalOncology Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record